Management of acral myxoinflammatory fibroblastic sarcoma

Ajay Tejwani, Wendy Kobayashi, Yen Lin Evelyn Chen, Andrew E. Rosenberg, Sam Yoon, Kevin A. Raskin, Daniel I. Rosenthal, Gunnlaugur P. Nielsen, Francis J. Hornicek, Thomas F. Delaney

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Background: Acral myxoinflammatory fibroblastic sarcoma (AMFS) is a rare, low-grade sarcoma that commonly affects the distal extremities. From the published cases, therapy for AMFS to date has been comprised of excision or amputation, with limited use of radiotherapy (RT) or chemotherapy. In this report, the outcome of 17 patients with AMFS treated at the study institution was reported. Methods: A retrospective review of all cases of AMFS identified in the Sarcoma Database in the Department of Radiation Oncology at the study institution was conducted. Treatment records and data from follow-up visits of patients were reviewed. Results: Seventeen patients were identified. All the patients underwent surgical resection (15 excisions and 2 amputations). Positive surgical margins after excisions were noted in 5 patients and were widely positive in 1 patient. Of the 17 patients, 14 patients received some form of RT. The average total dose was 56.4 Gray (Gy). Eight patients received preoperative RT alone, 5 patients received preoperative RT and postoperative RT, and 1 patient received preoperative RT and intraoperative RT. Median follow-up was 24.5 months. One patient presented with recurrent disease and was treated with resection, and both pre- and postoperative RT. He was free of disease 23 months after his last treatment. No local recurrence was noted in the remaining patients. Of the 14 patients undergoing preoperative RT, complete pathologic necrosis or no tumor was noted in 1 of the patients. No metastatic disease was observed in any of the patients. There was no significant radiation toxicity observed in any of the patients. Conclusions: Data were consistent with local control of distal extremity sarcomas with resection and RT, suggesting that limb-sparing surgery with this treatment combination is an appropriate option in the limb-sparing control of patients with AMFS, even those with positive surgical margins.

Original languageEnglish (US)
Pages (from-to)5733-5739
Number of pages7
JournalCancer
Volume116
Issue number24
DOIs
StatePublished - Dec 15 2010
Externally publishedYes

Keywords

  • acral myxoinflammatory fibroblastic sarcoma
  • radiotherapy
  • sarcoma
  • surgical resection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Management of acral myxoinflammatory fibroblastic sarcoma'. Together they form a unique fingerprint.

  • Cite this

    Tejwani, A., Kobayashi, W., Chen, Y. L. E., Rosenberg, A. E., Yoon, S., Raskin, K. A., Rosenthal, D. I., Nielsen, G. P., Hornicek, F. J., & Delaney, T. F. (2010). Management of acral myxoinflammatory fibroblastic sarcoma. Cancer, 116(24), 5733-5739. https://doi.org/10.1002/cncr.25567